Hoth Therapeutics Inc (HOTH)

$1.04 0.00 (N/A)
Market Cap 15.98M
Revenue (ttm) 0.00
Net Income (ttm) -8.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 381,100
Avg Vol 588,588
Day's Range N/A - N/A
Shares Out 15.51M
Stochastic %K 27%
Beta 0.50
Analysts Strong Sell
Price Target $4.50

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 756 2997
Address:
1177 Avenue of the Americas, Suite 5066 5th Floor, New York, United States
Denker327
Denker327 Mar. 17 at 5:58 PM
$HOTH Falling as expected. It’ll end the week in the low .90’s.
1 · Reply
Love_To_Learn
Love_To_Learn Mar. 17 at 1:19 PM
$HOTH MADE A CHANGE TO U ALSO SHUFFLED 25 MILLION SHARES AROUND OF THE BOOKS!
0 · Reply
thefly2
thefly2 Mar. 16 at 7:11 PM
$HOTH Maintaining very well considering the current market.
0 · Reply
Johnnyb1973
Johnnyb1973 Mar. 16 at 10:42 AM
$HOTH Any day now she's gonna explode! Like 3x-5x from here!
1 · Reply
SCEDIT
SCEDIT Mar. 13 at 7:17 PM
$HOTH if you're able to lockdown the range this plays, you can make $ on ups and downs. Maybe someone can run the numbers and see what are the highs and lows for the last 3, 6 months, or 1 or 2 years
0 · Reply
thefly2
thefly2 Mar. 13 at 3:33 PM
$HOTH still holding all shares
0 · Reply
StockScanners
StockScanners Mar. 13 at 4:27 AM
$HOTH reached 1.26
0 · Reply
Tino321
Tino321 Mar. 12 at 10:28 PM
$HOTH either we will come out big or another biotech scam lol
0 · Reply
Ccutting21
Ccutting21 Mar. 12 at 6:35 PM
$HOTH What is happening with this slug?
0 · Reply
thefly2
thefly2 Mar. 12 at 5:48 PM
$HOTH deserves more
0 · Reply
Latest News on HOTH
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Mar 10, 2026, 8:13 AM EDT - 7 days ago

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Mar 4, 2026, 8:31 AM EST - 13 days ago

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Feb 24, 2026, 4:15 PM EST - 21 days ago

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Feb 10, 2026, 8:30 AM EST - 5 weeks ago

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study

Feb 10, 2026, 8:01 AM EST - 5 weeks ago

EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Feb 5, 2026, 8:03 AM EST - 5 weeks ago

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Jan 22, 2026, 8:13 AM EST - 7 weeks ago

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Jan 21, 2026, 8:13 AM EST - 7 weeks ago

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Jan 15, 2026, 8:17 AM EST - 2 months ago

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Jan 2, 2026, 8:13 AM EST - 2 months ago

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Dec 3, 2025, 2:00 PM EST - 3 months ago

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Dec 1, 2025, 8:03 AM EST - 3 months ago

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Nov 20, 2025, 8:13 AM EST - 4 months ago

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Oct 27, 2025, 7:49 AM EDT - 5 months ago

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Oct 21, 2025, 8:23 AM EDT - 5 months ago

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Oct 8, 2025, 8:02 AM EDT - 5 months ago

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Oct 7, 2025, 7:57 AM EDT - 5 months ago

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Sep 24, 2025, 8:13 AM EDT - 6 months ago

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Sep 16, 2025, 8:14 AM EDT - 6 months ago

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Sep 10, 2025, 8:29 AM EDT - 6 months ago

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Sep 4, 2025, 8:16 AM EDT - 6 months ago

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Sep 2, 2025, 8:16 AM EDT - 7 months ago

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Jul 29, 2025, 7:58 AM EDT - 8 months ago

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jul 22, 2025, 8:19 AM EDT - 8 months ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 25, 2025, 8:27 AM EDT - 9 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 24, 2025, 10:36 AM EDT - 9 months ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 23, 2025, 8:03 AM EDT - 9 months ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 1:34 PM EDT - 9 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 18, 2025, 8:22 AM EDT - 9 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 16, 2025, 8:00 AM EDT - 9 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 12, 2025, 9:17 AM EDT - 9 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 11, 2025, 8:28 AM EDT - 9 months ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 10 months ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

May 12, 2025, 7:30 AM EDT - 11 months ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 17, 2025, 8:01 AM EDT - 11 months ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 15, 2025, 8:19 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Apr 2, 2025, 7:58 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 31, 2025, 4:45 PM EDT - 1 year ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 26, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 18, 2025, 8:06 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 10, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 5, 2025, 1:40 PM EST - 1 year ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Mar 4, 2025, 8:16 AM EST - 1 year ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Feb 10, 2025, 8:22 AM EST - 1 year ago

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jan 24, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Jan 21, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Jan 17, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Jan 8, 2025, 1:27 PM EST - 1 year ago

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Jan 7, 2025, 11:53 AM EST - 1 year ago

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Denker327
Denker327 Mar. 17 at 5:58 PM
$HOTH Falling as expected. It’ll end the week in the low .90’s.
1 · Reply
Love_To_Learn
Love_To_Learn Mar. 17 at 1:19 PM
$HOTH MADE A CHANGE TO U ALSO SHUFFLED 25 MILLION SHARES AROUND OF THE BOOKS!
0 · Reply
thefly2
thefly2 Mar. 16 at 7:11 PM
$HOTH Maintaining very well considering the current market.
0 · Reply
Johnnyb1973
Johnnyb1973 Mar. 16 at 10:42 AM
$HOTH Any day now she's gonna explode! Like 3x-5x from here!
1 · Reply
SCEDIT
SCEDIT Mar. 13 at 7:17 PM
$HOTH if you're able to lockdown the range this plays, you can make $ on ups and downs. Maybe someone can run the numbers and see what are the highs and lows for the last 3, 6 months, or 1 or 2 years
0 · Reply
thefly2
thefly2 Mar. 13 at 3:33 PM
$HOTH still holding all shares
0 · Reply
StockScanners
StockScanners Mar. 13 at 4:27 AM
$HOTH reached 1.26
0 · Reply
Tino321
Tino321 Mar. 12 at 10:28 PM
$HOTH either we will come out big or another biotech scam lol
0 · Reply
Ccutting21
Ccutting21 Mar. 12 at 6:35 PM
$HOTH What is happening with this slug?
0 · Reply
thefly2
thefly2 Mar. 12 at 5:48 PM
$HOTH deserves more
0 · Reply
Johnnyb1973
Johnnyb1973 Mar. 12 at 4:11 PM
$HOTH Hell yeah! 🤟🏻🇺🇸
0 · Reply
BearyBullish4U
BearyBullish4U Mar. 12 at 4:09 PM
$HOTH Flying under the radar. Wait until they find it. Hold your shares!
0 · Reply
thefly2
thefly2 Mar. 12 at 4:08 PM
$HOTH looking good
0 · Reply
Richricx
Richricx Mar. 12 at 3:00 PM
$HOTH $1.50 $1.80 $2.10 🚀
0 · Reply
BucksNRoses
BucksNRoses Mar. 12 at 2:57 PM
$HOTH 👀👀
0 · Reply
Richricx
Richricx Mar. 12 at 2:57 PM
$HOTH Broke the 200MA Look at that MACD
0 · Reply
Richricx
Richricx Mar. 12 at 2:54 PM
$HOTH
0 · Reply
stonkmamma
stonkmamma Mar. 12 at 2:52 PM
$HOTH would love to see something parabolic. It’s been a while.
0 · Reply
stonkmamma
stonkmamma Mar. 12 at 2:52 PM
$HOTH this app is as bad as Facebook now with its fascist controls…. What you’re seeing is filtered content— don’t forget it
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 12 at 2:48 PM
$HOTH There u go as alerted below👇 this is the 200..can it break?? 🥊 🥊
1 · Reply
Love_To_Learn
Love_To_Learn Mar. 12 at 2:40 PM
$HOTH 1.22 IS ME * BEEN ACCUMULATING A BIT
0 · Reply
stonkmamma
stonkmamma Mar. 12 at 2:33 PM
$HOTH case you don’t know what the hell is happening here… Hoth Therapeutics currently has four main programs in its pipeline: HT-001 (lead, in Phase 2), HT-KIT (orphan-designated, preclinical/IND-enabling), HT-ALZ (preclinical for Alzheimer’s), and a GDNF-based metabolic/obesity program (preclinical). Target 10 🎯
0 · Reply